GLP-1 receptor agonists showed no increased risk of adverse events compared to other antiobesity medications in patients who had previously undergone bariatric surgery.
No increased risk (aOR 1.1)GLP-1 receptor agonists showed the same adverse event rate as non-GLP-1 weight loss medications in post-bariatric surgery patients
What the researchers found
GLP-1RA use was not associated with higher odds of adverse events compared to FDA-approved non-GLP-1 medications (aOR 1.1, 95% CI 0.5–2.6) or off-label medications (aOR 1.1, 95% CI 0.6–2.3). Notably, starting any antiobesity medication 12 or more months after surgery was associated with dramatically lower risk of adverse events compared to earlier initiation (aOR 0.01, 95% CI 0.0–0.01, p < 0.001).
Why it matters
Many bariatric surgery patients regain weight and need additional medications. Concerns about GLP-1 drug safety in this population — including delayed gastric emptying in an already altered GI anatomy — have limited prescribing. This study provides reassurance that GLP-1 drugs are as safe as alternatives in these patients.
The numbers in context
Patients had laparoscopic Roux-en-Y gastric bypass or sleeve gastrectomy. Compared FDA-approved, off-label, and GLP-1RA antiobesity medications.
How the study worked
Single-center retrospective cohort study of 599 patients aged 16-65 who underwent gastric bypass or sleeve gastrectomy and later initiated antiobesity medications. Patients categorized by medication type (GLP-1RA vs. non-GLP-1RA). Primary outcome: adverse event incidence. Univariate and multivariate logistic regression for risk factors.
Who was studied
Post-bariatric surgery patients aged 16-65 who started antiobesity medications
What this study cannot tell us
Single-center retrospective design with potential selection bias. Only 123 GLP-1 users — may be underpowered for rare events. No specific adverse event breakdown by type. Unable to determine causation. Timing finding (≥12 months safer) may reflect recovery rather than medication timing specifically.
How to read the evidence
Rated moderate: retrospective cohort from a single academic center with 599 patients. Adequate for safety signal detection but limited for rare events.
When this study was published
Published in 2024. Addresses a contemporary clinical question as GLP-1 drugs are increasingly prescribed to post-bariatric populations.
The bigger picture
As GLP-1 drugs become first-line weight management tools, understanding their safety in special populations like post-bariatric patients is essential. This study fills a key evidence gap and may encourage more confident prescribing.
Questions still open
- Why is starting weight loss medication earlier after surgery associated with more adverse events?
- Are there differences in specific adverse event types between GLP-1 and non-GLP-1 medications?
- What is the optimal timing and dose for starting GLP-1 drugs after bariatric surgery?
Common questions
Is it safe to take Ozempic after gastric bypass or sleeve surgery?
When is the best time to start weight loss drugs after bariatric surgery?
Read the original research
Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.
Diabetes, obesity & metabolism, 26(9), 3906-3913
Citation
Samuels, Jason M; Niswender, Kevin D; Roumie, Christianne L; Spann, Matthew D; Flynn, C Robb; Ye, Fei; Blankush, Joseph; Irlmeier, Rebecca; Funk, Luke M; Patel, Mayur B. (2024). Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.. Diabetes, obesity & metabolism, 26(9), 3906-3913. https://doi.org/10.1111/dom.15737